Establishment and genomic characterization of mouse xenografts of human primary prostate tumors

American Journal of Pathology

Volumn 176, Issue 4, 2010, Pages 1901-1913

  Priolo, Carmen ^a   Agostini, Michelle ^a   Vena, Natalie ^a   Ligon, Azra H ^a   Fiorentino, Michelangelo ^a   Shin, Eyoung ^a   Farsetti, Antonella ^b   Pontecorvi, Alfredo ^b   Sicinska, Ewa ^a   Loda, Massimo ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENETIC TRAIT; GENOME; GLEASON SCORE; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IN VIVO STUDY; KIDNEY CAPSULE; MALE; MOUSE; NONHUMAN; PRIMARY PROSTATE TUMOR; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE TUMOR; XENOGRAFT;

EID: 77950592442     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.090873     Document Type: Article

References (33)

1. D'Amico AV, Whittington R, Malkowicz SB, Weinstein M, Tomaszewski JE, Schultz D, Rhude M, Rocha S, Wein A, Richie JP: Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol 2001, 166:2185-2188 (Pubitemid 33065253)
2. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen CM: Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007, 177:2106-2131 (Pubitemid 46726449)
3. Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, Ma J, Fiorentino M, Kurth T, Loda M, Giovannucci EL, Rubin MA, Mucci LA: Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 2009, 27:3459-3464
4. Sobel RE, Sadar MD: Cell lines used in prostate cancer research: a compendium of old and new lines-part 2. J Urol 2005, 173:360-372
5. Sobel RE, Sadar MD: Cell lines used in prostate cancer research: a compendium of old and new lines-part 1. J Urol 2005, 173:342-359
6. Cespedes MV, Casanova I, Parreno M, Mangues R: Mouse models in oncogenesis and cancer therapy. Clin Transl Oncol 2006, 8:318-329
7. Van Dyke T, Jacks T: Cancer modeling in the modern era: progress and challenges. Cell 2002, 108:135-144 (Pubitemid 34161134)
8. Roy-Burman P, Wu H, Powell WC, Hagenkord J, Cohen MB: Genetically defined mouse models that mimic natural aspects of human prostate cancer development. Endocr Relat Cancer 2004, 11:225-254 (Pubitemid 38832827)
9. Garber K: Realistic rodents? Debate grows over new mouse models of cancer. J Natl Cancer Inst 2006, 98:1176-1178
10. Peehl DM: Are primary cultures realistic models of prostate cancer? J Cell Biochem 2004, 91:185-195
11. Pretlow TG, Wolman SR, Micale MA, Pelley RJ, Kursh ED, Resnick MI, Bodner DR, Jacobberger JW, Delmoro CM, Giaconia JM, Pretlow TP: Xenografts of primary human prostatic carcinoma. J Natl Cancer Inst 1993, 85:394-398 (Pubitemid 23073158)
12. van Weerden WM, de Ridder CM, Verdaasdonk CL, Romijn JC, van der Kwast TH, Schroder FH, van Steenbrugge GJ: Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am J Pathol 1996, 149:1055-1062
13. Nanni S, Priolo C, Grasselli A, D'Eletto M, Merola R, Moretti F, Gallucci M, De Carli P, Sentinelli S, Cianciulli AM, Mottolese M, Carlini P, Arcelli D, Helmer-Citterich M, Gaetano C, Loda M, Pontecorvi A, Bacchetti S, Sacchi A, Farsetti A: Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer. Mol Cancer Res 2006, 4:79-92
14. Migita T, Ruiz S, Fornari A, Fiorentino M, Priolo C, Zadra G, Inazuka F, Grisanzio C, Palescandolo E, Shin E, Fiore C, Xie W, Kung AL, Febbo PG, Subramanian A, Mucci L, Ma J, Signoretti S, Stampfer M, Hahn WC, Finn S, Loda M: Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst 2009, 101:519-532
15. Firestein R, Bass AJ, Kim SY, Dunn IF, Silver SJ, Guney I, Freed E, Ligon AH, Vena N, Ogino S, Chheda MG, Tamayo P, Finn S, Shrestha Y, Boehm JS, Jain S, Bojarski E, Mermel C, Barretina J, Chan JA, Baselga J, Tabernero J, Root DE, Fuchs CS, Loda M, Shivdasani RA, Meyerson M, Hahn WC: c17 CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature 2008; 455:547-551
16. Protopopov A, Feng B, Chin L: Full complexity genomic hybridization on 60-mer oligonucleotide microarrays for array comparative genomic hybridization (aCGH). Methods Mol Biol 2008, 439:87-100
17. Visonneau S, Cesano A, Torosian MH, Miller EJ, Santoli D: Growth characteristics and metastatic properties of human breast cancer xenografts in immunodeficient mice. Am J Pathol 1998, 152:1299-1311 (Pubitemid 28221882)
18. Kubota T, Yamaguchi H, Watanabe M, Yamamoto T, Takahara T, Takeuchi T, Furukawa T, Kase S, Kodaira S, Ishibiki K, Kitajima M: Growth of human tumor xenografts in nude mice and mice with severe combined immunodeficiency (SCID). Surg Today 1993, 23:375-377 (Pubitemid 23107579)
19. Kumar-Sinha C, Shah RB, Laxman B, Tomlins SA, Harwood J, Schmitz W, Conzelmann E, Sanda MG, Wei JT, Rubin MA, Chinnaiyan AM: Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer. Am J Pathol 2004, 164:787-793 (Pubitemid 38235461)
20. Moser FG, Dorman BP, Ruddle FH: Mouse-human heterokaryon analysis with a 33258 Hoechst-Giemsa technique. J Cell Biol 1975, 66:676-680
21. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648 (Pubitemid 41528150)
22. Ishkanian AS, Mallof CA, Ho J, Meng A, Albert M, Syed A, van der Kwast T, Milosevic M, Yoshimoto M, Squire JA, Lam WL, Bristow RG: High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer. Prostate 2009, 69:1091-1100
23. Tu JJ, Rohan S, Kao J, Kitabayashi N, Mathew S, Chen YT: Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol 2007, 20:921-928 (Pubitemid 47267823)
24. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360:1320-1328
25. Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Chung LW, Greenberg NM, Hahn WC, Isaacs JT, Navone NM, Peehl DM, Simons JW, Solit DB, Soule HR, VanDyke TA, Weber MJ, Wu L, Vessella RL: The current state of preclinical prostate cancer animal models. Prostate 2008, 68:629-639 (Pubitemid 351614641)
26. Rangarajan A, Weinberg RA: Opinion: comparative biology of mouse versus human cells: modelling human cancer in mice. Nat Rev Cancer 2003, 3:952-959 (Pubitemid 37500180)
27. Naumov GN, Akslen LA, Folkman J: Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 2006, 5:1779-1787
28. Loeb S, Catalona WJ: Prostate-specific antigen in clinical practice. Cancer Lett 2007, 249:30-39
29. Wang Y, Revelo MP, Sudilovsky D, Cao M, Chen WG, Goetz L, Xue H, Sadar M, Shappell SB, Cunha GR, Hayward SW: Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate 2005, 64:149-159 (Pubitemid 40791764)
30. Lapointe J, Li C, Giacomini CP, Salari K, Huang S, Wang P, Ferrari M, Hernandez-Boussard T, Brooks JD, Pollack JR: Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res 2007, 67:8504-8510 (Pubitemid 47437424)
31. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM: Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008, 8:497-511
32. Yoshimoto M, Cunha IW, Coudry RA, Fonseca FP, Torres CH, Soares FA, Squire JA: FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 2007, 97:678-685 (Pubitemid 47339893)
33. McCall P, Witton CJ, Grimsley S, Nielsen KV, Edwards J: Is PTEN loss associated with clinical outcome measures in human prostate cancer? Br J Cancer 2008, 99:1296-1301